Pregnancy and Lactation Evidence Across the FDA CDER Novel Drug Lifecycle: A Descriptive Study of Public Documentation for Drugs Approved 2015-2023

Scritto il 15/11/2026
da Chengliang Wang

Ther Innov Regul Sci. 2026 Nov 15. doi: 10.1007/s43441-026-01071-2. Online ahead of print.

ABSTRACT

BACKGROUND: Public records do not routinely show how trial eligibility, labeling and postmarketing studies relate for the same drug. Although an unlinked label statement may have supporting evidence, the available records can limit what an external reader can determine about that relationship.

OBJECTIVE: To describe pregnancy and lactation documentation for FDA CDER novel drugs approved during 2015-2023.

METHODS: We examined public documents for 415 drugs, including trial eligibility records, initial and current label sections 8.1-8.3, postmarketing requirements or commitments (PMR/PMC), and pregnancy registries. Seven predefined categories summarized the available records and recorded label changes. Missing or unresolved information was retained. Analyses were descriptive.

RESULTS: The complete chain category comprised 33 drugs (8.0%). Two documentation patterns accounted for 182 (43.9%): PMR/PMC or registry records without a recorded label change (97, 23.4%), and recorded label changes without traceable PMR/PMC or registry records (85, 20.5%). Label change used the broader measure including recorded sections 8.3 changes (133/415); newly identified human pregnancy or lactation information was recorded separately (56/415). PMR/PMC or registry status remained unresolved for 111 drugs.

CONCLUSIONS: These findings describe the public records examined, not the absence of underlying evidence or the adequacy of regulatory decisions. Clearer links among public documents would support reproducible comparisons.

PMID:43034979 | DOI:10.1007/s43441-026-01071-2